216 related articles for article (PubMed ID: 19220422)
1. Aberrant p53 protein expression and function in a panel of hematopoietic cell lines with different p53 mutations.
Kamihira S; Terada C; Sasaki D; Yanagihara K; Tsukasaki K; Hasegawa H; Yamada Y
Eur J Haematol; 2009 Apr; 82(4):301-7. PubMed ID: 19220422
[TBL] [Abstract][Full Text] [Related]
2. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
Liu Y; Bodmer WF
Proc Natl Acad Sci U S A; 2006 Jan; 103(4):976-81. PubMed ID: 16418264
[TBL] [Abstract][Full Text] [Related]
3. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
4. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M; Elstrodt F; Klijn JG; Berns EM; Schutte M
Breast Cancer Res Treat; 2006 Sep; 99(1):97-101. PubMed ID: 16541312
[TBL] [Abstract][Full Text] [Related]
5. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
[TBL] [Abstract][Full Text] [Related]
6. 3-Methylcholanthrene inactivates the p53 gene in Syrian hamster embryo fibroblasts by inducing a specific intronic point mutation.
Albor A; Flessate DM; Soussi T; Notario V
Cancer Res; 1994 Aug; 54(16):4502-7. PubMed ID: 8044802
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas.
Cote RJ; Jhanwar SC; Novick S; Pellicer A
Cancer Res; 1991 Oct; 51(19):5410-6. PubMed ID: 1913660
[TBL] [Abstract][Full Text] [Related]
8. Analysis of p53 gene mutations in human glioma cell lines.
Koga H; Zhang S; Washiyama K; Ichikawa T; Onda K; Kumanishi T
Noshuyo Byori; 1996 Apr; 13(1):1-10. PubMed ID: 8916120
[TBL] [Abstract][Full Text] [Related]
9. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
10. Spectra of X-ray-induced and spontaneous intragenic HPRT mutations in closely related human cells differentially expressing the p53 tumor suppressor gene.
Phillips EN; Gebow D; Liber HL
Radiat Res; 1997 Feb; 147(2):138-47. PubMed ID: 9008205
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of a novel germ line p53 mutation in familial gastric cancer in the Japanese population.
Yamada H; Shinmura K; Okudela K; Goto M; Suzuki M; Kuriki K; Tsuneyoshi T; Sugimura H
Carcinogenesis; 2007 Sep; 28(9):2013-8. PubMed ID: 17690113
[TBL] [Abstract][Full Text] [Related]
12. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.
Bodner SM; Minna JD; Jensen SM; D'Amico D; Carbone D; Mitsudomi T; Fedorko J; Buchhagen DL; Nau MM; Gazdar AF
Oncogene; 1992 Apr; 7(4):743-9. PubMed ID: 1565469
[TBL] [Abstract][Full Text] [Related]
13. Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124.
Smardová J; Pavlová S; Svitáková M; Grochová D; Ravcuková B
Oncol Rep; 2005 Oct; 14(4):901-7. PubMed ID: 16142349
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
15. Lymphoblastoid cell lines differing in p53 status show clear differences in basal gene expression with minor changes after irradiation.
Zschenker O; Borgmann K; Streichert T; Meier I; Wrona A; Dikomey E
Radiother Oncol; 2006 Aug; 80(2):236-49. PubMed ID: 16905214
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
[TBL] [Abstract][Full Text] [Related]
17. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
18. Mutations of the p53 gene in human myeloma cell lines.
Mazars GR; Portier M; Zhang XG; Jourdan M; Bataille R; Theillet C; Klein B
Oncogene; 1992 May; 7(5):1015-8. PubMed ID: 1373872
[TBL] [Abstract][Full Text] [Related]
19. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines.
Davidoff AM; Pence JC; Shorter NA; Iglehart JD; Marks JR
Oncogene; 1992 Jan; 7(1):127-33. PubMed ID: 1741160
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity and p53 expression in Pterygium.
Reisman D; McFadden JW; Lu G
Cancer Lett; 2004 Mar; 206(1):77-83. PubMed ID: 15019163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
